Endocrine Disorders: Evaluation and Management

  • Author: Todd T. Brown, MD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 11/14/16 (What's New)

Summary

  • Patients at risk for progression to diabetes mellitus and cardiovascular disease require close monitoring, including those who meet the following criteria:
    • Impaired fasting glucose, defined as a fasting glucose concentration of 100-125 mg/dL
    • Impaired glucose tolerance, defined as a 2-hour glucose concentration during an oral glucose tolerance test of 140-199 mg/dL

Action required